Evidence map›Paper›PMID 22410406›Full record

ArticleMedical care2012

Disparities in receipt of antiretroviral therapy among HIV-infected adults (2002-2008).

John A Fleishman, Baligh R Yehia, Richard D Moore, Kelly A Gebo, Allison L Agwu, HIV Research Network

Abstract read
In one paragraph

Article in Medical care, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Observational
  3. Article
  4. Review
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Health insurance coverage for persons in HIV care, 2006-2012.Journal of acquired immune deficiency syndromes (1999) · 2014
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

John A FleishmanCenter for Financing, Access, and Cost Trends, Agency for Healthcare Research and Quality, Rockville, MD 20850, USA. john.fleishman@ahrq.hhs.gov
Baligh R Yehia
Richard D Moore
Kelly A Gebo
Allison L Agwu
HIV Research Network

Funding

HIV DISEASE OUTCOMES IN DRUG USERS IN CLINICAL PRACTICER01DA011602 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 1998 to 2013
$10.8M
MID CAREER INVESTIGATOR AWARDK24DA000432 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2000 to 2009
$1.5M
Alcohol and HIV Treatment and Clinical ProgressionR01AA016893 · NIAAA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2008 to 2011
$1.3M
HAART Initiation in Behaviorally HIV-Infected YouthK23AI084549 · NIAID · JOHNS HOPKINS UNIVERSITY · PI AGWU, ALLISON L · 2010 to 2013
$537k
NIAAA NIH HHS R01 AA016893NIAAA NIH HHS R01 AA 16893NIAID NIH HHS K23 AI084549NIDA NIH HHS K24 DA000432NIDA NIH HHS K24 DA 00432NIDA NIH HHS R01 DA011602NIDA NIH HHS R01DA11602PHS HHS 060025
6 · The paper itself

Abstract

objectivePrior research has documented sociodemographic disparities in the use of antiretroviral therapy (ART). Recent therapeutic developments and changing epidemiological profiles may have altered such disparities. We examine the extent to which sociodemographic differences in prescribed ART have changed between 2002 and 2008.

methodsWe analyzed data abstracted from medical records at 13 US sites participating in the Human Immunodeficiency Virus Research Network. Prescription of ART was assessed for each year in care for each patient. A total of 14,092 patients were followed up for 39,251 person-years. We examined ART use as a function of sex, race/ethnicity, human immunodeficiency virus risk group, age, and CD4 history (no test <500 cells/mm, one or more tests between 500 and 350 cells/mm, 1 test ≤350 cells/mm, and 2 or more tests ≤350 cells/mm). Using multiple logistic regression, we ascertained interactions between each of these variables and calendar year.

resultsThe overall percentage prescribed ART increased from 60% to 80% between 2002 and 2008. Among those with 2 or more CD4 tests ≤350 cells/mm, the percentage increased from 82% to 92%. ART rates were higher for those with lower CD4 counts but increased over time for all CD4 groups and for all demographic groups. Nevertheless, sex and racial/ethnic disparities persisted. Significant interactions were obtained for CD4 history by year, age by year, and age by CD4 history.

conclusionsAlthough prescription of ART became more widespread from 2002 to 2008, patients who were female, black, or younger still had lower ART rates than male, white, or older patients.

Indexed as

AdolescentAdultAge FactorsAnti-Retroviral AgentsCD4 Lymphocyte CountFemaleHealthcare DisparitiesHIV InfectionsHumansInsurance CoverageMaleMiddle AgedRisk FactorsSex FactorsSocioeconomic FactorsUnited StatesAnti-Retroviral Agents

Identifiers

PMID22410406
PMCPMC3779806

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.